CoChat

UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia

Open access
Benyoucef, Aissa, Palii, Carmen G., Wang, Chaochen, Porter, Christopher J., Chu, Alphonse, Dai, Fengtao, Tremblay, Véronique, Rakopoulos, Patricia, Singh, Kulwant, Huang, Suming, Pflumio, Francoise, Hébert, Josée, Couture, Jean-Francois, Perkins, Theodore J., Ge, Kai, Dilworth, F. Jeffrey, Brand, Marjorie · 2016 · Genes & Development
Cited by 125

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous group of hematological tumors composed of distinct subtypes that vary in their genetic abnormalities, gene expression signatures, and prognoses. However, it remains unclear whether T-ALL subtypes differ at the functional level, and, as such, T-ALL treatments are uniformly applied across subtypes, leading to variable responses between patients. Here we reveal the existence of a subtype-specific epigenetic vulnerability in T-ALL by which a particular subgroup of T-ALL characterized by expression of the oncogenic transcription factor TAL1 is uniquely sensitive to variations in the dosage and activity of the histone 3 Lys27 (H3K27) demethylase UTX/KDM6A. Specifically, we identify UTX as a coactivator of TAL1 and show that it acts as a major regulator of the TAL1 leukemic gene expression program. Furthermore, we demonstrate that UTX, previously described as a tumor suppressor in T-ALL, is in fact a pro-oncogenic cofactor essential for leukemia maintenance in TAL1-positive (but not TAL1-negative) T-ALL. Exploiting this subtype-specific epigenetic vulnerability, we propose a novel therapeutic approach based on UTX inhibition through in vivo administration of an H3K27 demethylase inhibitor that efficiently kills TAL1-positive primary human leukemia. These findings provide the first opportunity to develop personalized epigenetic therapy for T-ALL patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.276790.115

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 125

Metadata

Authors
Benyoucef, A., Palii, C. G., Wang, C., Porter, C. J., Chu, A., Dai, F., Tremblay, V., Rakopoulos, P., Singh, K., Huang, S., Pflumio, F., Hébert, J., Couture, J.-F., Perkins, T. J., Ge, K., Dilworth, F. J., & Brand, M.
Venue
Genes & Development
Published
2016-03-01
Volume
30
Issue
5
Pages
508-521
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2288988715
Cited by
125
References
10
Type
posted content
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1101/gad.276790.115
The paper
Benyoucef, A., Palii, C. G., Wang, C., Porter, C. J., Chu, A., Dai, F., Tremblay, V., Rakopoulos, P., Singh, K., Huang, S., Pflumio, F., Hébert, J., Couture, J.-F., Perkins, T. J., Ge, K., Dilworth, F. J., & Brand, M. (2016). UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Genes & Development. https://doi.org/10.1101/gad.276790.115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.